ArticleThe EMBO journal1994
Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors.
Article in The EMBO journal, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 142 citations in OpenAlex.
- Development of a specific anti-human EphA3 monoclonal antibody, EaBiochemistry and biophysics reports · 2025Article
- Ephrin-Eph receptor tyrosine kinases for potential therapeutics against hepatic pathologies.Journal of cell communication and signaling · 2023Review
- Identification of Myelin Basic Protein Proximity Interactome Using TurboID Labeling Proteomics.Cells · 2023Article
- mRNA expression analysis of the hippocampus in a vervet monkey model of fetal alcohol spectrum disorder.Journal of neurodevelopmental disorders · 2022Article
- The Roles of EphB2 in Cancer.Frontiers in cell and developmental biology · 2022Review
- Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer.Scientific reports · 2018Article
- Eph receptors and ephrins as targets for cancer therapy.Journal of cellular and molecular medicine · 2012Review
- EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.Molecular and cellular biology · 2012Article
- EphA receptor signaling--complexity and emerging themes.Seminars in cell & developmental biology · 2012Review
- Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice.PloS one · 2012Article
- EphB3 limits the expansion of neural progenitor cells in the subventricular zone by regulating p53 during homeostasis and following traumatic brain injury.Stem cells (Dayton, Ohio) · 2010Article
- Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1.Molecular and cellular biology · 2010Article
- Regulation of process retraction and cell migration by EphA3 is mediated by the adaptor protein Nck1.Biochemistry · 2009Article
- Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.Oncogene · 2008Article
- The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.Molecular cancer research : MCR · 2008Review
- Eph/ephrin signaling: networks.Genes & development · 2008Review
- Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Tyr-298 in ephrinB1 is critical for an interaction with the Grb4 adaptor protein.The Biochemical journal · 2004Article
- Growth factor signaling pathways in vascular development.Oncogene · 1999Review
- Neurotractin, a novel neurite outgrowth-promoting Ig-like protein that interacts with CEPU-1 and LAMP.The Journal of cell biology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A family of tyrosine kinase receptors related to the product of the eph gene has been described recently. One of these receptors, elk, has been shown to be expressed only in brain and testes. Using a direct expression cloning technique, a ligand for the elk receptor has been isolated by screening a human placenta cDNA library with a fusion protein containing the extracellular domain of the receptor. This isolated cDNA encodes a transmembrane protein. While the sequence of the ligand cDNA is unique, it is related to a previously described sequence known as B61. Northern blot analysis of human tissue mRNA showed that the elk ligand's mRNA is 3.5 kb long and is found in placenta, heart, lung, liver, skeletal muscle, kidney and pancreas. Southern blot analysis showed that the gene is highly conserved in a wide variety of species. Both elk ligand and B61 mRNAs are inducible by tumour necrosis factor in human umbilical vein endothelial cells. In addition, both proteins show promiscuity in binding to the elk and the related hek receptors. Since these two ligand sequences are similar, and since elk and hek are members of a larger family of eph-related receptor molecules, we refer to these ligands as LERKs (ligands for eph-related kinases).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.